Test Code ADEMM Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum
Additional Codes
| EPIC EAP | Mayo |
| LAB5322 | DYS2 |
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, refer to Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number, the duplicate test will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering healthcare professional's name, phone number, mailing address, and email address
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended before starting immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Useful For
Investigating idiopathic dysautonomic symptoms
Directing a focused search for cancer in patients with idiopathic dysautonomia
Investigating autonomic symptoms that appear in the course or wake of cancer therapy and are not explainable by recurrent cancer or metastasis (detection of autoantibodies in this profile helps differentiate autoimmune dysautonomia from the effects of chemotherapy)
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ADEI | Dysautonomia, Interpretation, S | No | Yes |
| GANG | AChR Ganglionic Neuronal Ab, S | No | Yes |
| ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
| APBIS | AP3B2 IFA, S | No | Yes |
| CRMS | CRMP-5-IgG, S | No | Yes |
| CS2CS | CASPR2-IgG CBA, S | No | Yes |
| DPPCS | DPPX Ab CBA, S | No | Yes |
| LG1CS | LGI1-IgG CBA, S | No | Yes |
| PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AN1BS | ANNA-1 Immunoblot, S | No | No |
| AN2BS | ANNA-2 Immunoblot, S | No | No |
| DPPTS | DPPX Ab IFA Titer, S | No | No |
| AN1TS | ANNA-1 Titer, S | No | No |
| APBCS | AP3B2 CBA, S | No | No |
| APBTS | AP3B2 IFA Titer, S | No | No |
| CRMTS | CRMP-5-IgG Titer, S | No | No |
| PC2TS | PCA-2 Titer, S | No | No |
| CRMWS | CRMP-5-IgG Western Blot, S | Yes | No |
Method Name
ADEI: Medical Interpretation
ANN1S, AN1TS, APBIS, APBTS, DPPTS, PCAB2, PC2TS, CRMS, CRMTS: Indirect Immunofluorescence Assay (IFA)
APBCS, CS2CS, DPPCS, LG1CS: Cell Binding Assay (CBA)
CRMWS: Western Blot (WB)
AN1BS, AN2BS: Immunoblot (IB)
GANG: Radioimmunoassay (RIA)
Reporting Name
Dysautonomia, Autoimm/Paraneo, SSpecimen Type
SerumSpecimen Minimum Volume
2.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Day(s) Performed
Report Available
8 to 12 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83519
86255 x 7
84182 AN1BS (if appropriate)
86256 AN1TS (if appropriate)
84182 AN2BS (if appropriate)
86255 APBCS (if appropriate)
86256 APBTS (if appropriate)
86256 CRMTS (if appropriate)
84182 CRMWS (if appropriate)
86256 DPPTS (if appropriate)
86256 PC2TS (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| DYS2 | Dysautonomia, Autoimm/Paraneo, S | 99000-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 80150 | ANNA-1, S | 33615-6 |
| 83077 | CRMP-5-IgG, S | 72504-4 |
| 84321 | AChR Ganglionic Neuronal Ab, S | 94694-7 |
| 83138 | PCA-2, S | 84925-7 |
| 34270 | Dysautonomia, Interpretation, S | 69048-7 |
| 64279 | LGI1-IgG CBA, S | 94287-0 |
| 64281 | CASPR2-IgG CBA, S | 94285-4 |
| 64933 | DPPX Ab CBA, S | 94676-4 |
| 615863 | AP3B2 IFA, S | 101907-4 |
| 618892 | IFA Notes | 48767-8 |